Compare AXTI & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AXTI | NRIX |
|---|---|---|
| Founded | 1986 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.5B |
| IPO Year | 1998 | 2020 |
| Metric | AXTI | NRIX |
|---|---|---|
| Price | $71.36 | $26.72 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | ★ $50.50 | $30.50 |
| AVG Volume (30 Days) | ★ 11.5M | 999.6K |
| Earning Date | 04-30-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $99,361,000.00 | $76,987,000.00 |
| Revenue This Year | $44.70 | N/A |
| Revenue Next Year | $42.23 | $48.05 |
| P/E Ratio | $461.56 | ★ N/A |
| Revenue Growth | 31.09 | ★ 99.31 |
| 52 Week Low | $2.68 | $8.20 |
| 52 Week High | $143.16 | $28.23 |
| Indicator | AXTI | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 49.50 | 64.21 |
| Support Level | $65.02 | $14.63 |
| Resistance Level | $71.49 | N/A |
| Average True Range (ATR) | 10.26 | 0.98 |
| MACD | 0.30 | 0.02 |
| Stochastic Oscillator | 26.80 | 75.95 |
AXT Inc is a developer and producer of compound and single element semiconductor substrates, also known as wafers. The dominant substrates used in producing semiconductor chips and other electronic circuits are made from silicon. It is engaged in the design, development, manufacture, and distribution of high-performance compound semiconductor substrates and the sale of materials. The company provides alternative or specialty materials in the form of substrates or wafers, including compound and single-element substrates. Its compound substrates combine indium with phosphorous or gallium with arsenic. Geographically firm has its business presence across the region of Europe, Japan, Taiwan, China, North America, and the Asia Pacific from which China derives its maximum revenue to the company.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.